此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels (ATTACH)

2026年11月1日 更新者:Young-Suk Lim、Asan Medical Center

A Multicenter, Open-label, Single Arm Trial for the Effectiveness of Antiviral Treatment in Cirrhotic Patients With Low-level Hepatitis B Virus DNA Levels With a Comparison to Matched Historical Controls (ATTACH)

Multicenter, Open-label, Single arm Trial with Matched Historical controls. Male and female adults with compensated liver cirrhosis due to chronic hepatitis B virus infection who have low-level viremia.

To assess the efficacy of Tenofovir Alafenamide (TAF) in reducing liver-related events (hepatocellular carcinoma, liver-related events and death, decompensated liver cirrhosis) in cirrhotic chronic hepatitis B patients with low-level viremia compared with matched historical controls.

研究概览

地位

主动,不招人

干预/治疗

详细说明

  1. This clinical trial is a multicenter, open label, single arm study in cirrhotic chronic hepatitis B patients with low-level viremia.

  2. Approximately 200 subjects meeting eligibility criteria will be enrolled and randomized (1:2) to Treatment Arm (A) or , Matched Historical Controls Arm (B), as below:

    • Treatment Arm (A): 200 subjects, TAF 25mg once daily with food for 3 years
    • Matched Historical Controls Arm (B): 400 subjects, patients who did not receive antiviral treatment during their follow-up period, and matched with the treatment group in a 1:1 ratio according to their baseline characteristics
  3. Treatment Arm is scheduled to be followed up to 3 years.

The analysis population of this study consists of the Full Analysis Set (FAS), which can evaluate efficacy. The treatment group includes patients who received any dose of study medication (TAF), while the control group consists of patients who did not receive antiviral treatment and were matched by propensity score (PS) from those under observation. Unless otherwise specified, the FAS will be used for primary and secondary efficacy endpoints.

Statistical analyses for the primary efficacy endpoint will be performed at a two-sided significance level of 5%, aligned with the sample size calculation.

PS will be estimated using logistic regression, incorporating variables such as age, gender, HBeAg positivity, HBV DNA level, ALT, platelet count, albumin, total bilirubin, creatinine, prothrombin time, diabetes, hypertension, and family history of hepatocellular carcinoma. The groups will be matched 1:2 using nearest neighbor matching. Baseline characteristics between the matched groups will be compared using standardized mean difference (SMD), with an absolute SMD <0.1 indicating good balance.

The 3-year cumulative incidence of the primary endpoint will be estimated using the Kaplan-Meier method. For comparisons between PS-matched groups, a Cox proportional hazards model with robust variance estimation will be used to account for matching, reporting HR and 95% confidence intervals.

For hepatocellular carcinoma incidence, mortality, liver transplantation, decompensated liver function (Child-Pugh score ≥8), and cirrhosis-related complications, 1-, 2-, and 3-year incidence rates will be estimated with Kaplan-Meier. Cox models with robust variance will be used for group comparisons, reporting HR and 95% confidence intervals.

HBsAg loss and viral response (HBV DNA <15 IU/mL) are binary outcomes, summarized by frequency and proportion in each group. Comparisons will be made using a Poisson regression model with Generalized Estimating Equations (GEE), reporting relative risk (RR) and 95% confidence intervals.

Fibroscan changes, treatment response, duration, and health-related quality of life by disease status (hepatitis, cirrhosis, hepatocellular carcinoma) will be analyzed using GEE, accounting for the matched-pair design.

In the PS-matched retrospective control group, the 1-, 2-, and 3-year cumulative probabilities of initiating antiviral therapy due to serum HBV DNA ≥2,000 IU/mL will be estimated via Kaplan-Meier.

Two official analyses will be conducted: an interim analysis (using data collected by October 2024) and a final analysis. No correction for type 1 error inflation from multiple testing will be applied in the interim analysis.

For sensitivity analysis, multivariable analyses will be performed using the unmatched dataset for primary and secondary endpoints. Depending on outcome type, Cox models and Poisson regression will be employed, using the covariates from the PS estimation for adjustment.

研究类型

介入性

注册 (估计的)

600

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Daegu、韩国
        • Kyungpook National University Hospital
      • Seoul、韩国
        • Asan Medical Center
      • Seoul、韩国
        • Korea University Guro Hospital
      • Seoul、韩国
        • Seoul National University Hospital
      • Seoul、韩国
        • Seoul National University Bundang Hospital
      • Seoul、韩国
        • Konkuk University Hospital
      • Seoul、韩国
        • Chung-Ang University Hospital
      • Seoul、韩国
        • Kyung-Hee University Hospital
      • Seoul、韩国
        • Samsung Medical center
      • Ulsan、韩国
        • Ulsan University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

30年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Willing and able to provide written informed consent prior to study entry

  2. Age ≥30 years and ≤80 years at the time of screening

  3. Chronic hepatitis B infection defined as HBsAg (+) or HBV DNA (+) for at least 6 months prior to the Screening visit, or medical records indication a chronic hepatitis B virus infection by meeting all of the following criteria at the time of screening. (1) HBsAg (+), (2) HBV DNA (+), and (3) HBcAb IgM (-)

  4. Either HBeAg (+) or HBeAg (-)

  5. Serum HBV DNA levels ≥20 IU/mL and <2,000 IU/mL at the time of screening

  6. Evidence of liver cirrhosis defined as meeting any of the following criteria:

    • Radiological evidence of liver cirrhosis by ultrasound, CT, or MRI
    • Platelet count <150,000 /mm3
    • Presence of esophageal or gastric varices by endoscopy in 2 years before the timing of screening
    • Clinically significant portal hypertension
    • Fibroscan ≥12.0 kPa (if the test was done in 6 months before the time of screening)
  7. Estimated creatinine clearance ≥30 ml/min (by calculation of creatinine clearance or using the CKD-EPI equation)

  8. Ability to comply with all study requirements

Exclusion Criteria:

  1. Confirmed known co-infection with HCV, HIV, or HDV
  2. Current alcohol (60g/day) or substance abuse judged by the investigator that will potentially interfere with subject compliance
  3. Any history of, or current evidence of, clinical hepatic decompensation (e.g., ascites, encephalopathy, variceal hemorrhage, or Child-Pugh score of ≥8, with the exception of Gilbert syndrome) in 1 year before the time of screening
  4. Currently on or have received therapy with Interferon or immunosuppressant (including systemic chemotherapy) within 12 months prior to the screening
  5. Requirement for chronic use of systemic immunosuppressant including, but not limited to, corticosteroid (prednisone equivalent of >40 mg/day for >2 weeks), azathioprine, or monoclonal antibodies
  6. Received solid organ or bone marrow transplant
  7. History of severe, life-threatening or other significant sensitivity to any excipients of the study drugs
  8. Any other clinical conditions (cardiovascular, respiratory, neurologic, or renal conditions) or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements.
  9. Currently on or have received antiviral treatment for ≥ 2 weeks within 6 months prior to the screening
  10. History or current evidence of hepatocellular carcinoma (HCC), or high α-fetoprotein (AFP) > 20 ng/mL. But, the patients with AFP > 20 ng/mL can be enrolled if AFP shows decreasing trend and there is no evidence of HCC by dynamic CT or MRI)
  11. Malignancy other than hepatocellular carcinoma within the 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (within 2 years prior to screening with confirmation of no evidence of disease). Subjects under evaluation for possible malignancy are not eligible.
  12. Concurrent enrollment in another clinical study for other type of antiviral treatment for CHB or immune modulatory drug within 3 months prior to randomization, participation to an observational (non-interventional) clinical studies or interventional studies not using anti-HBV or immune modulatory drugs, or during the follow-up period of an interventional study are not exclusion criteria.
  13. Pregnant women, women who are breastfeeding or who believe they may wish to become pregnant during the course of the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Antiviral Treatment

Tenofovir Alafenamide 25mg once daily , Oral

Tenofovir Alafenamide 25 mg oral once daily

其他名称:
  • 替诺福韦艾拉酚胺
无干预:Matched Historical Controls

Patients who did not receive antiviral treatment during their follow-up period, and matched with the treatment group in a 1:2 ratio according to their baseline characteristics

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Cumulative incidence rate of composite clinical events
大体时间:From randomization the composite clinical events will be collected every 6weeks , assessed up to 36months

hepatocellular carcinoma, death, liver transplantation, decompensated liver cirrhosis defined as Child-Pugh score ≥8, liver cirrhosis-related complications,liver-related unexpected hospital admission

From randomization the composite clinical events will be collected every 6weeks , assessed up to 36months

次要结果测量

结果测量
措施说明
大体时间
Cumulative incidence
大体时间:From randomization the composite clinical events will be collected every 1year , assessed up to 3years

Death, hepatocellular carcinoma , Liver transplantation, decompensated liver cirrhosis, liver cirrhosis-related complications, subjects with HBsAg seroclearance, subjects with HBV DNA <15 IU/mL, Serial changes of liver stiffness assessed by Fibroscan

From randomization the composite clinical events will be collected every 1year , assessed up to 3years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Young-Suk Lim, PhD、Asan Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年8月23日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2021年3月1日

首先提交符合 QC 标准的

2021年3月1日

首次发布 (实际的)

2021年3月3日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月1日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅